evipedia.ai
← Back

Indole-3-Lactic Acid for Health & Longevity

Evidence Review created on 09/20/2026 using AI4L / Opus 5

Also known as: ILA, Indolelactic Acid, Indole Lactic Acid, 3-Indolelactic Acid, Indole-3-Lactate, Indolelactate, 2-Hydroxy-3-(1H-indol-3-yl)propanoic Acid

Motivation

Indole-3-lactic acid is a small molecule that gut bacteria make from the dietary amino acid tryptophan. Certain bifidobacteria and lactobacilli carry the enzyme needed to produce it, and the amount circulating in a person’s blood therefore depends less on what they eat than on which microbes they host. Interest in the compound grew once researchers noticed that it binds a sensor inside human cells that helps set the tone of the immune system in the gut, the brain and the skin.

The compound was first described decades ago as a minor product of protein breakdown and was long treated as metabolic background noise. Attention shifted when breastfed infants colonized by particular milk-adapted bifidobacteria were found to carry strikingly high levels of it, alongside a calmer intestinal immune profile. Since then it has been measured in blood, urine and stool across a wide range of conditions, sometimes as a marker of health and sometimes as a marker of disease.

This review examines what is known about indole-3-lactic acid: how it is produced, what raising or lowering it appears to do, where the evidence is human and where it is not, and what remains unresolved.

Benefits - Risks - Protocol - Conclusion

This section lists sources that give a substantive overview of indole-3-lactic acid (ILA), the bacterial tryptophan metabolite under review.

No qualifying content was found from any of the priority experts, and fewer than five priority-platform items are therefore listed. Searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com and lifespan.io returned nothing that treats this compound in depth. The closest match is a short FoundMyFitness news item in which indole-3-lactic acid appears only as one measured metabolite in a study of an environmental pollutant, which does not meet the depth bar for inclusion. The list above was therefore drawn from the primary and narrative-review literature, and has not been padded.

Grokipedia

No Grokipedia article exists for indole-3-lactic acid. The site carries pages for neighbouring indole compounds, including indole-3-acetic acid, indole-3-butyric acid and indole-3-carbinol, but none for this metabolite.

Examine

No Examine article exists for indole-3-lactic acid. The site’s own search returns no results for the compound, which is consistent with its coverage being organised around ingredients sold as supplements rather than bacterial metabolites.

ConsumerLab

No ConsumerLab article exists for indole-3-lactic acid. ConsumerLab tests finished consumer products, and no product on the market declares this compound as an ingredient, so there is nothing for the site to assay.

Systematic Reviews

The reviews below are the systematic reviews and meta-analyses that bear on indole-3-lactic acid, none of which evaluates the compound as an administered intervention.

The trade-off at the centre of this review is covered on both sides: the claimed anti-inflammatory and mood effects are represented by the inflammatory bowel disease, osteoarthritis and depression reviews, and the principal risk is represented by the cardiovascular cohort review. What no systematic review covers is the compound given to humans, because only one small proof-of-concept trial has administered it and there is nothing yet to pool.

Mechanism of Action

Gut bacteria build indole-3-lactic acid from tryptophan in two steps: a transaminase (an enzyme that transfers an amino group) yields indole-3-pyruvate, and an aromatic lactate dehydrogenase (an enzyme reducing aromatic keto acids) yields the lactic acid form (Laursen et al., 2021). Bifidobacteria also salvage free indole, precursor of the kidney toxin indoxyl sulfate, into this pathway — work from Morinaga Milk Industry, which sells producing strains (Yong et al., 2024).

Two receptors carry most of the signal. The first is the aryl hydrocarbon receptor (AhR, a sensor inside cells that switches genes on when it binds small aromatic molecules). Binding induces CYP1A1 (an enzyme that breaks down aromatic compounds), releases interleukin-22 (a repair signal) from gut immune cells, and suppresses NF-κB (nuclear factor kappa B, the master switch for inflammatory genes), lowering interleukin-8 from gut lining cells (Ehrlich et al., 2020). The second, hydroxycarboxylic acid receptor 3 (HCA3, a hydroxy-acid receptor unique to humans and great apes), alters T-cell and monocyte behaviour.

A competing account holds that key effects bypass it: in colorectal cancer cells it occupies a phosphorylation site on STAT3 (a transcription factor driving growth and survival), shutting down glucose burning even when the receptor is blocked (Zhou et al., 2025).

Pharmacologically it is a weak-to-moderate agonist, not a selective drug. In mice, oral doses are absorbed, cross the blood-brain barrier and hold steady brain concentrations (Tang et al., 2026). No human half-life is published; clearance appears largely renal, levels climbing as filtration falls (Cheng et al., 2020).

Historical Context & Evolution

Indole-3-lactic acid entered the literature as an analytical curiosity. Mid-twentieth-century work on tryptophan handling detected it in urine, and by the 1970s it was catalogued among the indolic compounds that accumulate in people with failing kidneys (Byrd et al., 1976). In that setting it was read as waste: a retention solute sitting alongside indoxyl sulfate, interesting mainly because it marked impaired clearance. Plant scientists knew it separately as a minor relative of the growth regulator indole-3-acetic acid.

The reframing came from infant nutrition rather than kidney medicine. Screening of bifidobacteria isolated from breastfed infants, by a group at Morinaga Milk Industry, which sells such strains, showed that infant-adapted strains produce far more of it than other species (Sakurai et al., 2019). A group at Massachusetts General Hospital then identified it as the molecule in Bifidobacterium longum subsp. infantis culture fluid that quietens the inflammatory response of immature intestinal cells (Meng et al., 2020), and a Danish group found the responsible enzyme and tied fecal concentrations to receptor activity in infants.

Opinion has not settled. The early reading treated the compound as waste; the reading that followed treated it as a beneficial signal. Recent work found the same molecule blunting responses to cancer immunotherapy (Zhou et al., 2026), and newborn blood concentrations tracking later attention deficits (Widdowson et al., 2026). Neither framing has been retired; what changed is that both now carry evidence, and the compound’s effect appears to depend on tissue, timing and amount.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the class of evidence that would be required — a human clinical endpoint or a validated clinical surrogate measured under administration of the compound, in more than one trial — does not exist, because the only trial that has administered the compound to people is a single proof-of-concept skin study.

Medium 🟩 🟩

Lower Odds of Symptomatic Hand Osteoarthritis ⚠️ Conflicted

Adults with more indole-3-lactic acid in plasma have lower odds of painful hand osteoarthritis (joint degeneration causing pain and stiffness in the fingers). The finding comes from a community-based cohort of 1,359 people and was reproduced in an independent 142-person cohort (Wei et al., 2023). Both are observational, so reverse causation and confounding remain open, and a meta-analysis of the wider gut-joint literature found no significant pooled association for tryptophan-pathway markers. Net reading: the inverse association is specific to this metabolite and unconfirmed for the pathway as a whole.

Magnitude: Each 0.1 log10-unit increase in plasma indole-3-lactic acid carried an odds ratio (OR, the ratio of the odds of an outcome between two groups) of 0.85 (95% confidence interval, CI, the range in which the true value most likely lies, 0.72–1.00) in the 1,359-person discovery cohort, and 0.70 (95% CI 0.53–0.92) in the 142-person validation cohort.

Lower Intestinal Inflammation

Fecal concentrations run inversely to disease activity in inflammatory bowel disease (chronic immune-driven inflammation of the intestine): the compound suppresses epithelial CCL2 and CCL7 (proteins recruiting inflammatory white blood cells), reducing inflammatory macrophages (Yu et al., 2023). A systematic review of intestinal metabolome studies found the indole pathway shifted in active disease, and a randomised infant trial from Morinaga Milk Industry, which sells the strain, lowered fecal calprotectin as this metabolite rose (Xu et al., 2026). Human data are observational for the metabolite itself; causal direction is untested.

Magnitude: Direction only: fecal indole-3-lactic acid falls as inflammatory bowel disease activity rises, and the relationship holds across samples taken during active disease; the literature reports no outcome figure, because no study has quantified a change in disease activity per unit of the metabolite.

Skin Barrier Support and Reduced Skin Inflammation

Skin bacteria produce the compound, and in skin cells and mouse skin it strengthens barrier genes and suppresses inflammatory mediators. A proof-of-concept clinical trial reported in the same paper found topical application reduced transepidermal water loss and eased atopic dermatitis (an itchy, relapsing inflammatory skin disease) symptoms (Zhang et al., 2026). This is the only setting in which the compound itself has been given to people, in a single small unblinded trial, and it bears on skin rather than on systemic ageing.

Magnitude: Direction only: topical application reduced transepidermal water loss and eased symptoms in the proof-of-concept trial reported alongside the laboratory work; the paper gives no effect size or per-unit outcome figure for the metabolite.

Low 🟩

Support for Mood via the Bacteria That Produce It

Circulating concentrations rise in human volunteers given bifidobacteria carrying the producing enzyme, and antidepressant effects in mice disappear when that enzyme is knocked out (Qian et al., 2024). The human limb measured the metabolite, not mood, so the evidence is indirect.

Magnitude: Not quantified in available studies. No controlled trial has given the compound to people and measured a mood outcome; the human data extend only to circulating concentrations rising during bifidobacteria supplementation.

Speculative 🟨

Suppression of Colorectal Tumour Growth

In mice and patient-derived tumour organoids it slows proliferation, promotes tumour-cell death and primes killer T cells (Zhang et al., 2023; Sugimura et al., 2021). Basis is animal and laboratory work only.

Reduced Amyloid Accumulation and Cognitive Protection

In a mouse model of Alzheimer’s disease it lowered soluble amyloid-beta and prevented cognitive decline via receptor activation in brain immune cells (Kim et al., 2024). Basis is animal work; human support is correlational only.

In aged mice it reduced intestinal permeability and systemic inflammation, and lowered cell-ageing markers in aged blood-vessel cells (Liu et al., 2025). Basis is animal and cell work; no human ageing outcome exists.

Improved Insulin Sensitivity

In a cellular model of insulin resistance the compound restored glucose uptake by raising mitochondrial complex IV activity and lowering oxidative stress (Zhan et al., 2026). Mechanistic only; no controlled human glucose data exist.

Benefit-Modifying Factors

  • Secretor status (FUT2 gene): FUT2 (an enzyme adding fucose sugars to gut and milk glycans) determines which milk oligosaccharides and mucin sugars are available. Non-secretors carry fewer of the bifidobacteria that make the compound, so probiotic and prebiotic routes may yield less of it.

  • Aryl hydrocarbon receptor variants: Human populations carry receptor alleles differing in ligand affinity, and CYP1A1 inducibility varies with them. A low-affinity receptor blunts the downstream response to any given concentration, so the same blood level does not mean the same signal.

  • Baseline concentration: Headroom matters. People with multiple sclerosis and with hand osteoarthritis show reduced levels, whereas people with reduced kidney filtration show elevated levels that reflect retention rather than production, and further elevation there carries no implied benefit.

  • Pre-existing conditions: Active inflammatory bowel disease, chronic kidney disease and ongoing cancer immunotherapy each change what a higher concentration means — from plausibly favourable, to a clearance artefact, to a possible liability.

  • Sex: Established sex-based differences are absent. Tumour suppression was demonstrated in both male and female mice, while the anorexia and Alzheimer’s synbiotic (probiotic plus its feeding fibre) work used female animals only. No human study has reported a sex-stratified benefit for this metabolite.

  • Age: Concentrations peak in breastfed infancy and fall sharply after weaning as the producing bifidobacteria recede. Adults, and particularly older adults with reduced bifidobacterial abundance, sit at the low end, which is where the ageing-related animal work locates the opportunity.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the class of evidence that would be required — a documented adverse event or validated clinical surrogate recorded under administration of the compound, in more than one trial — does not exist, because the compound has been given to people in only one small proof-of-concept skin trial.

Medium 🟥 🟥

Higher Circulating Levels Track Cardiovascular Events and Death

In patients undergoing elective cardiac evaluation, the tryptophan branch running through indole-3-pyruvate to indole-3-lactic acid was among the microbial pathways whose products predicted major adverse cardiovascular events (MACE, meaning heart attack, stroke or death) and all-cause mortality over three years, independent of standard risk factors (Nemet et al., 2023). Two independent cohorts totalling 4,833 people showed the pattern, and a separate systematic review of prospective cohorts also placed indole derivatives on the adverse side. The data are observational and cannot separate cause from marker.

Magnitude: Direction only: products of the indole-3-pyruvate-to-indole-3-lactic-acid branch were associated with more three-year major adverse cardiovascular events and poorer survival, holding independently of traditional risk factors across a 4,000-person US cohort and an 833-person European cohort; the report gives no separate outcome figure for indole-3-lactic acid alone.

Reduced Response to Cancer Immunotherapy ⚠️ Conflicted

Among 122 patients with esophageal cancer on anti-PD-1 therapy (drugs releasing a brake called programmed cell death protein 1 on immune T cells), non-responders were enriched for Ligilactobacillus salivarius and the indole-3-lactic acid it makes; the metabolite suppressed the precursor killer T cells that sustain a response (Zhou et al., 2026). Other work reports the opposite, the compound priming killer T cells against colorectal tumours (Zhang et al., 2023). Net reading: direction depends on tumour type and immune context rather than being uniform.

Magnitude: Direction only: non-response to anti-PD-1 therapy accompanied higher tumour and stool indole-3-lactic acid in the index cohort of 122 patients and in two validation cohorts; the paper reports the association and its mechanism without an outcome figure per unit of the metabolite.

Elevated Newborn Levels Linked to Later Attention Deficits

In the COPSAC birth cohort, higher indole-3-lactic acid in newborn dried blood spots mediated the link between first-week gut Bifidobacterium abundance and a diagnosis of attention-deficit/hyperactivity disorder at age ten, after adjustment for genetic and early-life factors; the metabolite-outcome association replicated in two independent cohorts (Widdowson et al., 2026). The observation concerns the first week of life specifically, and does not extend to adult exposure, but it is the clearest human signal that more of this metabolite is not uniformly better.

Magnitude: Direction only: higher newborn blood indole-3-lactic acid accompanied higher odds of an attention-deficit/hyperactivity disorder diagnosis at age ten, replicated across two additional cohorts; the finding is reported as a mediation of the bacterial association rather than as an outcome figure for the metabolite.

Low 🟥

Accumulation When Kidney Filtration Falls

Blood and urine concentrations rise in chronic kidney disease (progressive loss of kidney filtering capacity) and track creatinine, urea and inflammatory markers (Hong et al., 2024). Genetic analysis places the arrow at reduced filtration raising the metabolite (Cheng et al., 2020), so the concern is accumulation, not injury.

Magnitude: Plasma indole-3-lactic acid carried an odds ratio of 4.49 for chronic kidney disease, and urinary indole-3-lactic acid an odds ratio of 2.14, in a study of 47 patients and 30 healthy controls; Mendelian randomisation (a method using inherited genetic variants to infer causal direction) placed the causal arrow at lower filtration raising the metabolite.

Speculative 🟨

Immune Dampening From Sustained Receptor Activation

Continuous aryl hydrocarbon receptor activation is an established route to immune tolerance and is exploited by some tumours. Whether a sustained external load reproduces that is untested; the basis is mechanistic only.

Central Nervous System Exposure and Appetite Effects

Oral dosing in mice crosses the blood-brain barrier and remodels appetite-regulating gene expression in the hypothalamus (Tang et al., 2026). No human data exist; the basis is animal work only.

Unknown Consequences in Pregnancy

It promotes placental cell migration and invasion through receptor signalling (Wei et al., 2025). Framed as favourable in preeclampsia (a pregnancy blood-pressure disorder), its effect in normal pregnancy is unstudied. Basis is isolated cell reports.

Risk-Modifying Factors

  • Kidney function: Reduced filtration is the dominant modifier. Because clearance is largely renal, any exogenous load accumulates disproportionately once estimated filtration falls below roughly 60 mL/min/1.73 m², and the accumulation is greatest in dialysis-dependent disease.

  • Active cancer immunotherapy: Patients on anti-PD-1 therapy sit in the one human setting where higher concentrations have accompanied worse outcomes, and the signal was strongest in esophageal squamous cell carcinoma rather than in every tumour type.

  • Aryl hydrocarbon receptor variants: A high-affinity receptor allele amplifies both the anti-inflammatory and the immune-suppressing arms of the same signal, so genotype shifts where a given concentration sits between benefit and immune dampening. No clinical genotyping guidance exists.

  • Baseline concentration: An already-elevated plasma level usually signals reduced clearance rather than high production. Adding to it compounds a retention problem, which is why the measured starting value changes the meaning of any increase.

  • Sex: No sex-based difference in risk has been reported for this metabolite in humans. The neurodevelopmental cohort work was not sex-stratified, and the animal safety observations come predominantly from female mice.

  • Age: Newborns carry the highest concentrations and the only human adverse neurodevelopmental signal. At the older end of the adult range, declining kidney filtration is the age-related factor that matters most for accumulation.

Key Interactions & Contraindications

  • Checkpoint inhibitors — drugs releasing immune brakes on tumours (pembrolizumab, nivolumab, atezolizumab): Caution. Higher concentrations accompanied non-response in esophageal cancer. Consequence: possible loss of antitumour response. Mitigation: the metabolite is not deliberately raised during therapy.

  • Statins — cholesterol-lowering drugs (atorvastatin, rosuvastatin, simvastatin): Additive, generally favourable. Part of the bowel-cancer-preventive effect of statins is mediated through microbial tryptophan breakdown products including this one. Consequence: overlapping mechanism. Mitigation: none needed; no dose change is described.

  • Broad-spectrum antibiotics (amoxicillin-clavulanate, ciprofloxacin, clindamycin): Caution. They deplete the bifidobacteria and lactobacilli that produce the compound. Consequence: sharp fall in production. Mitigation: probiotic dosing separated by two to four hours and continued past the course.

  • Proton pump inhibitors and antacids — drugs that reduce stomach acid (omeprazole, esomeprazole, calcium carbonate): Caution. Raising gut pH favours indole production over the lactic acid branch. Consequence: shift toward the kidney-toxic indoxyl sulfate route. Mitigation: maintained fermentable fibre intake, which lowers colonic pH.

  • Tryptophan and 5-HTP supplements (5-hydroxytryptophan, a serotonin precursor): Additive; caution. They supply the substrate for the whole pathway. Consequence: increased output of all downstream indoles, beneficial and adverse alike. Mitigation: high-dose tryptophan loading is avoided where kidney filtration is reduced.

  • Probiotics carrying the producing enzyme (Bifidobacterium longum, Bifidobacterium breve, Lactiplantibacillus plantarum): Additive and intended. Consequence: the principal practical route to raising the compound. Mitigation: none required; effects are dose-dependent on viable organisms delivered.

  • Prebiotic fibres (inulin, galacto-oligosaccharides, beta-glucan, resistant starch): Additive; no caution required. Fermentation feeds producers and suppresses competing indole production, because the bacteria use the easier sugars first. Consequence: higher output. Mitigation: gradual introduction limits gas and bloating.

  • Other interventions: Additive; no caution required. Fecal microbiota transplantation transfers the producing capacity wholesale, and exercise training raises circulating concentrations. Consequence: both shift the metabolite without any product being taken. Mitigation: both are accounted for when interpreting a measured change.

Populations who should avoid Indole-3-Lactic Acid:

  • Anyone receiving anti-PD-1 checkpoint immunotherapy, particularly for esophageal squamous cell carcinoma
  • Chronic kidney disease stage 4 or 5 (estimated filtration below 30 mL/min/1.73 m²) and anyone on dialysis
  • Pregnancy and breastfeeding, on the basis of the placental cell-model activity and the newborn neurodevelopmental signal
  • Preterm and term neonates outside a supervised trial, given the first-week association with later attention deficits
  • Anyone with a central venous catheter, severe immunosuppression or short bowel syndrome (too little functioning intestine to absorb nutrients normally) who cannot safely take live bacterial products, which are the only practical route

Risk Mitigation Strategies

  • Bacterial route rather than the compound: Production is raised with organisms carrying the enzyme rather than by ingesting research-grade material, mitigating the unknown-purity and unknown-dose exposure of a substance labelled not for human consumption.

  • Kidney filtration established before starting: Protocols measure estimated glomerular filtration rate with cystatin C and exclude tryptophan-loading strategies below 60 mL/min/1.73 m², mitigating accumulation from impaired renal clearance.

  • Pause during cancer immunotherapy: Probiotic, synbiotic and high-dose tryptophan strategies are suspended from two weeks before the first infusion until therapy ends, mitigating the association between higher concentrations and non-response.

  • Fibre rather than tryptophan loading: Regimens target 30–40 g of mixed fermentable fibre daily instead of gram-level tryptophan doses, mitigating the diversion of excess tryptophan into indoxyl sulfate and kynurenine.

  • Gradual fibre introduction: Increments of roughly 5 g per week to the target mitigate the bloating, cramping and stool-frequency changes that cause most people to abandon the approach within a fortnight.

  • Separation from antibiotics: Live organisms are dosed two to four hours apart from any antibiotic and continued for four weeks after the course, mitigating the collapse in production that follows antibiotic exposure.

  • Deferral in pregnancy and infancy: Deliberate strategies to raise the metabolite are deferred until after weaning, mitigating the placental and early-life neurodevelopmental signals, neither of which has a safe-exposure threshold.

Therapeutic Protocol

  • No direct protocol exists: No practitioner protocol administers the compound itself, because it is sold only as research material. Every regimen below raises it indirectly through the bacteria that produce it.

  • Infant-type bifidobacteria route: Bifidobacterium longum subsp. infantis at 8 × 10⁹ colony-forming units daily is the dose used in the trials that raised fecal concentrations, popularised by Evolve BioSystems and its successor Infinant Health.

  • Adult fermented-milk route: Bifidobacterium longum BB536 in fermented milk raised fecal concentrations in healthy adults within 17 days (Ejima et al., 2024). This approach was developed and trialled by Morinaga Milk Industry.

  • Competing approach — prebiotic first: A fibre-led regimen raises production without introducing an organism, by lowering colonic pH and freeing tryptophan from competing indole producers. Neither approach has been framed as superior in head-to-head work.

  • Best time of day: Live organisms are conventionally taken with or just before a meal, when gastric acidity is buffered. No circadian data specific to this metabolite exist to favour morning or evening.

  • Half-life: No human half-life has been published. In mice, oral doses are absorbed and hold steady brain and plasma concentrations over hours, which is consistent with daily rather than multiple-daily dosing.

  • Single versus split dosing: Trials that raised concentrations used a single daily dose of the producing organism. Splitting has not been tested and offers no described advantage, since output depends on colonisation rather than on peak delivery.

  • Genetic polymorphisms: FUT2 non-secretors sustain lower bifidobacterial colonisation and may need a longer run-in. Aryl hydrocarbon receptor affinity variants alter the downstream response, though no dosing guidance keyed to either exists.

  • Sex differences: No sex-based difference in response, dosing or effect has been established for this metabolite. Trials that raised concentrations enrolled both sexes without reporting stratified outcomes.

  • Age considerations: Response is greatest in infancy and falls after weaning. Older adults typically start from lower bifidobacterial abundance, so a longer run-in and attention to declining kidney filtration both apply.

  • Baseline biomarkers: A low starting fecal or plasma concentration predicts the largest proportional rise. An elevated starting plasma level usually reflects reduced clearance, in which case the regimen is inappropriate rather than promising.

  • Pre-existing conditions: Active inflammatory bowel disease, reduced kidney filtration and current cancer immunotherapy each change the calculation, the last two against proceeding at all.

Discontinuation & Cycling

  • Not a lifelong commitment: Nothing about the compound requires indefinite exposure. Fecal concentrations fall back toward baseline within weeks of stopping the producing organism, because colonisation by most adult probiotic strains is transient.

  • No withdrawal effects: No withdrawal syndrome has been described for the compound or for the bacteria that make it. Stopping returns production to whatever the resident microbiome supports, without rebound.

  • No tapering needed: Because there is no receptor down-regulation or dependence described, abrupt discontinuation carries no described consequence. Reducing fermentable fibre gradually is worthwhile only for digestive comfort.

  • Cycling not established: No cycling schedule has been tested for efficacy maintenance. The theoretical argument for periodic breaks rests on avoiding sustained receptor activation, not on any observed loss of effect over time.

  • Immediate stop situations: Regimens are discontinued before cancer immunotherapy begins, and if estimated filtration falls below 30 mL/min/1.73 m². Both are stop conditions rather than taper conditions, and neither requires a wash-out schedule.

Sourcing and Quality

  • Not sold as a supplement: No finished consumer product declares this compound. Material is available only as a laboratory reagent, labelled for research use and explicitly not for human consumption, so there is no consumer-grade supply chain to evaluate.

  • Reagent-grade identity: Suppliers including Cayman Chemical and Sigma-Aldrich list it under Chemical Abstracts Service number 1821-52-9, typically as the DL-form (an equal mix of the compound’s two mirror-image shapes). Certificates of analysis report purity by chromatography but not pharmaceutical-grade residual solvents.

  • Stereochemistry matters: Bacteria produce predominantly the D-form in the gut, while reagent material is usually the mixed DL-form. Whether the two mirror-image forms signal equivalently at the receptors involved has not been established in any human tissue.

  • Strain-level labelling in the bacterial route: Products naming the strain rather than only the species are the ones with published data, since only strains carrying the aromatic lactate dehydrogenase gene produce the compound. Examples include EVC001, M-63 and BB536.

  • Third-party testing: Colony-forming unit counts verified at end of shelf life rather than at manufacture, plus independent certification from NSF International, United States Pharmacopeia or ConsumerLab, address the common shortfall between labelled and delivered counts.

  • Reputable suppliers: Infinant Health supplies the EVC001 strain, and Morinaga Milk Industry supplies M-63 and BB536; both companies published the trials that raised concentrations, which is a commercial interest to weigh when reading those results.

Practical Considerations

  • Time to effect: Fecal concentrations rise within days to weeks on a producing organism; a healthy-adult trial detected significant increases by day 17 (Ejima et al., 2024). No human clinical outcome has been measured, so no time-to-benefit figure exists.

  • Common pitfalls: Buying research-grade material for personal use; choosing a probiotic by species rather than by strain; loading tryptophan instead of fibre, which diverts substrate into indoxyl sulfate; and abandoning fermentable fibre during the initial bloating phase.

  • Regulatory status: The compound itself is unapproved in any jurisdiction and holds no food or supplement authorisation. The bacterial route is regulated as a dietary supplement or food in most markets, with no claim permitted about this metabolite.

  • Measurement is hard to obtain: Quantifying the compound requires liquid chromatography with tandem mass spectrometry, available through research and specialty metabolomics panels rather than routine clinical laboratories. Most people pursuing this will be working without a measurement.

  • Cost and accessibility: The bacterial route runs roughly one to three US dollars a day and is widely available. Metabolomics panels that report the compound cost considerably more and are the genuine access barrier.

Interaction with Foundational Habits

  • Sleep: Indirect and unquantified. No study has measured this metabolite against sleep duration or quality. The plausible link runs through the circadian rhythm of the gut microbiota and its feeding-driven metabolic output, so keeping meal timing regular is the only practical consideration, and the direction of any effect is unestablished.

  • Nutrition: Direct and potentiating. Fermentable fibre is the single strongest lever: fibre-degrading bacteria cross-feed sugars to indole producers, which suppresses indole production and leaves more tryptophan for this branch. Low colonic pH from that same fermentation reinforces the shift. Inulin, beta-glucan and resistant starch act on this pathway more directly than isolated tryptophan doses.

  • Exercise: Direct and potentiating, with human evidence. In a randomised trial in relapsing-remitting multiple sclerosis, ten weeks of multimodal functional training raised the neuroprotection index built from this metabolite, and a single session raised its circulating concentration acutely (Wences Chirino et al., 2026). No timing relative to dosing is described.

  • Stress management: Indirect, direction favourable. Chronic stress lowers hippocampal concentrations in rodents, and bacteria that restore them reverse stress-induced behavioural change. No human stress-response data exist, so the practical consideration is that stress reduction supports the producing microbiome rather than acting on the metabolite directly.

Monitoring Protocol & Defining Success

A baseline panel establishes where the pathway sits and whether clearance is intact. It covers the metabolite itself in plasma or stool where a specialty laboratory is accessible, kidney filtration measured with cystatin C, high-sensitivity C-reactive protein as a general inflammation marker, fecal calprotectin where intestinal inflammation is the reason for interest, stool bifidobacteria abundance at species or strain resolution, and fasting serum tryptophan as a substrate check. Kidney filtration is the gating test, because a result below 60 mL/min/1.73 m² reframes any elevated metabolite as retention rather than production. Ongoing monitoring repeats kidney filtration and inflammation markers at 3 months, then every 6–12 months, with the metabolite and stool composition repeated at 3 months and again at 12 months, since shorter intervals mostly capture day-to-day dietary noise.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma indole-3-lactic acid No established target; track change from the individual’s own baseline Direct measure of systemic exposure Research and specialty metabolomics panels only; quantified by liquid chromatography with tandem mass spectrometry; no clinical reference interval has been ratified
Fecal indole-3-lactic acid No established target; track change from the individual’s own baseline Reflects colonic production rather than systemic exposure Stool tryptophan-metabolite panels; concentrations fall steeply after weaning, so infant reference values do not transfer to adults
hs-CRP Below 0.5 mg/L Tracks the low-grade inflammation the compound is proposed to lower High-sensitivity C-reactive protein, a general marker of systemic inflammation; conventional laboratories call anything below 3.0 mg/L normal; repeat if an infection occurred within two weeks
eGFR (cystatin C based) Above 90 mL/min/1.73 m² Falling filtration raises blood concentrations independently of production Estimated glomerular filtration rate, a calculated measure of kidney filtering capacity; the conventional threshold for concern is below 60; cystatin C avoids the muscle-mass bias of creatinine
Fecal calprotectin Below 50 µg/g Objective marker of intestinal inflammation, the best-supported target Conventional laboratories flag values above 150–200 µg/g; recent non-steroidal anti-inflammatory drug use raises it independently of disease
Stool Bifidobacterium relative abundance No established adult target; track change from the individual’s own baseline Indicates whether the producing organisms are actually present Sequencing-based; species or strain resolution is required, since only strains carrying the producing enzyme contribute
Serum tryptophan 45–75 µmol/L Substrate availability for the whole pathway Fasting sample; tryptophan competes with other large neutral amino acids for transport, so interpret alongside a full amino-acid panel where available

Qualitative markers worth tracking alongside the laboratory values:

  • Stool form and frequency, which respond to fermentable fibre before any metabolite shift is detectable
  • Abdominal bloating and gas, which indicate whether fibre was introduced too quickly
  • Energy levels through the afternoon, a non-specific but sensitive marker of gut-related inflammation
  • Cognitive clarity and mood stability, the domains where the animal work is most active and human data most absent
  • Skin comfort and barrier behaviour, given that resident skin bacteria produce the same compound

Emerging Research

  • Tryptophan for impaired receptor signalling in celiac disease: A 50-participant interventional study at McMaster University testing whether dietary tryptophan restores aryl hydrocarbon receptor signalling, with the Celiac Symptom Index as primary endpoint (NCT05576038). Recruiting.

  • Synbiotic modulation of gut-derived uremic toxins: A 30-participant study measuring changes in microbial metabolites, serum uremic toxins and inflammatory markers under a multispecies synbiotic (NCT07443280). Directly relevant to whether the pathway can be steered away from indoxyl sulfate. Recruiting.

  • Tryptophan metabolites in Parkinson’s disease: A 30-participant observational study comparing fecal tryptophan metabolite concentrations and microbial community structure between patients and controls (NCT07749261). Not yet recruiting.

  • The compound as a dietary biomarker: A completed 22-participant crossover study measuring plasma indole-3-lactic acid among candidate dietary biomarkers, including its 24-hour concentration-time profile (NCT05073523). The nearest thing to human pharmacokinetic data.

  • Future research that could weaken the case — immunotherapy interference: Whether the esophageal cancer finding generalises to other tumours is the most consequential open question (Zhou et al., 2026), and it points in the opposite direction to the colorectal work (Zhang et al., 2023).

  • Future research that could weaken the case — early-life exposure: Whether the newborn association with later attention deficits reflects the metabolite or the colonisation pattern that produces it remains unresolved (Widdowson et al., 2026).

  • Future research that could strengthen the case — ageing biology: Whether the reversal of intestinal barrier decline and systemic inflammation seen in aged mice holds in older adults is untested (Liu et al., 2025), and would be the first ageing-relevant human outcome.

  • Future research that could strengthen the case — cardiovascular direction: Whether the cardiovascular association is causal or a marker of impaired clearance needs a genetic-instrument analysis of the kind already applied to kidney function (Cheng et al., 2020).

Conclusion

Indole-3-lactic acid is not a supplement, a drug, or a food ingredient. It is a compound that certain gut bacteria build from a dietary amino acid, and almost everything known about it comes from measuring it in people or giving it to cells and animals.

In people it has almost always been observed rather than given, the one exception being a small skin study. Those observations point in more than one direction. Higher amounts in blood accompany lower odds of painful hand arthritis, and amounts fall when the bowel is inflamed. The same higher amounts also accompany more heart attacks, strokes and deaths among people undergoing heart testing, poorer responses to one class of cancer immune treatment, and reduced kidney filtration — though the kidney link appears to follow slower removal from the body rather than cause it.

The laboratory and animal record is far more striking than the human one: slower tumour growth, calmer brain inflammation, a tighter gut lining, gentler ageing of the immune system. None of it has been tested by giving the compound to a person, and effects that turn on tissue, timing and amount rarely survive that step unchanged.

The evidence base is young and uneven. Several of the human studies that drew attention to the compound were run by the companies selling the bacteria that produce it, which does not make the findings wrong but does shape which questions were asked. What it does at a chosen amount in a healthy adult is unmeasured.

Top - Benefits - Risks - Protocol